$4.73
0.64% yesterday
NYSE, Nov 25, 10:00 pm CET
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

ACELYRIN Stock price

$4.73
-1.24 20.77% 1M
+0.60 14.53% 6M
-2.73 36.60% YTD
-3.97 45.63% 1Y
-13.27 73.72% 3Y
-13.27 73.72% 5Y
-13.27 73.72% 10Y
NYSE, Closing price Mon, Nov 25 2024
+0.03 0.64%
ISIN
US00445A1007
Symbol
SLRN
Sector
Industry

Key metrics

Market capitalization $472.09m
Enterprise Value $-83.72m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.33
P/B ratio (TTM) P/B ratio 0.89
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-324.85m
Free Cash Flow (TTM) Free Cash Flow $-257.23m
Cash position $562.37m
EPS (TTM) EPS $-2.68
P/E forward negative
Short interest 5.38%
Show more

Is ACELYRIN a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

ACELYRIN Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a ACELYRIN forecast:

4x Buy
57%
3x Hold
43%

Analyst Opinions

7 Analysts have issued a ACELYRIN forecast:

Buy
57%
Hold
43%

Financial data from ACELYRIN

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.33 0.33
-
-
-0.33 -0.33
-
-
- Selling and Administrative Expenses 75 75
-
-
- Research and Development Expense 249 249
-
-
-325 -325
-
-
- Depreciation and Amortization 0.33 0.33
-
-
EBIT (Operating Income) EBIT -325 -325
-
-
Net Profit -264 -264
-
-

In millions USD.

Don't miss a Thing! We will send you all news about ACELYRIN directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ACELYRIN Stock News

Neutral
Seeking Alpha
12 days ago
Acelyrin, Inc. (NASDAQ:SLRN ) Q3 2024 Earnings Call November 13, 2024 4:30 PM ET Company Participants Tyler Marciniak - Vice President, Investor Relations and Corporate Affairs Mina Kim - Chief Executive Officer Gil Labrucherie - Chief Financial Officer and Chief Business Officer Shephard Mpofu - Chief Medical Officer Conference Call Participants Tyler Van Buren - TD Cowen Emily Bodnar - H.C. W...
Neutral
GlobeNewsWire
13 days ago
Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024
Neutral
GlobeNewsWire
20 days ago
LOS ANGELES, Nov. 06, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a conference call on Wednesday, November 13, 2024 at 4:30 p.m. ET to discuss its third quarter 2024 financial results and other corporate updates.
More ACELYRIN News

Company Profile

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Head office United States
CEO Mina Kim
Employees 130
Founded 2020
Website www.acelyrin.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today